These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31500572)

  • 1. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.
    Kendall EA; Malhotra S; Cook-Scalise S; Dowdy DW; Denkinger CM
    Clin Infect Dis; 2020 Dec; 71(11):2889-2896. PubMed ID: 31813958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.
    Goh JJN; Wang Q; Zhang N; de Castro Suarez N; Bustion AE; Nuermberger EL; Savic R
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0061524. PubMed ID: 39287403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
    Mudde SE; Ayoun Alsoud R; van der Meijden A; Upton AM; Lotlikar MU; Simonsson USH; Bax HI; de Steenwinkel JEM
    J Infect Dis; 2022 Jun; 225(11):1876-1885. PubMed ID: 33606880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TB Alliance regimen development for multidrug-resistant tuberculosis.
    Murray S; Mendel C; Spigelman M
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
    Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
    BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
    PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen.
    Zainabadi K; Vilbrun SC; Mathurin LD; Walsh KF; Pape JW; Fitzgerald DW; Lee MH
    J Infect Dis; 2024 Aug; 230(2):e447-e456. PubMed ID: 38060827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
    Otto-Knapp R; Edwards S; Kuchukhidze G; Kröger S; Häcker B; Bivol S; Yedilbayev A
    Euro Surveill; 2024 Apr; 29(17):. PubMed ID: 38666403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.
    Deng G; Fu L
    Lancet Infect Dis; 2024 Sep; 24(9):940-941. PubMed ID: 38768618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.